NeoImmuneTech Revenue and Competitors
Estimated Revenue & Valuation
- NeoImmuneTech's estimated annual revenue is currently $7.9M per year.
- NeoImmuneTech's estimated revenue per employee is $155,000
Employee Data
- NeoImmuneTech has 51 Employees.
- NeoImmuneTech grew their employee count by -31% last year.
NeoImmuneTech's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | SVP & Chief Scientific Officer | Reveal Email/Phone |
4 | Chief Clinical Officer | Reveal Email/Phone |
5 | Head CQA | Reveal Email/Phone |
6 | Director | Reveal Email/Phone |
7 | Director Clinical Development | Reveal Email/Phone |
8 | Senior Director, Head Clinical Operations Division | Reveal Email/Phone |
9 | Medical Director Drug Safety and Pharmacovigilance | Reveal Email/Phone |
10 | Project Manager Lead - Bioanalytical Operations | Reveal Email/Phone |
NeoImmuneTech Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | 0% | N/A | N/A |
#2 | $3.6M | 46 | -31% | $17.5M | N/A |
#3 | $3.6M | 46 | -34% | $10.5M | N/A |
#4 | $30.2M | 156 | 0% | $69.4M | N/A |
#5 | $11.8M | 76 | -15% | N/A | N/A |
#6 | $1.7M | 11 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $8.8M | 57 | 19% | N/A | N/A |
#9 | $0.2M | 1 | -86% | N/A | N/A |
#10 | $2M | 13 | 18% | N/A | N/A |
What Is NeoImmuneTech?
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on Twitter @neoimmunetech
keywords:N/A
N/A
Total Funding
51
Number of Employees
$7.9M
Revenue (est)
-31%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Rockville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.9M | 51 | 19% | N/A |
#2 | $7.1M | 51 | 34% | N/A |
#3 | $6.9M | 51 | -7% | N/A |
#4 | $6.7M | 51 | 0% | N/A |
#5 | $5.6M | 52 | 18% | N/A |